| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thiones | 27 | 2020 | 55 | 5.430 |
Why?
|
| Chromans | 28 | 2023 | 59 | 5.360 |
Why?
|
| Ovarian Neoplasms | 27 | 2025 | 595 | 4.470 |
Why?
|
| Antineoplastic Agents | 29 | 2020 | 678 | 3.070 |
Why?
|
| HSP70 Heat-Shock Proteins | 6 | 2025 | 49 | 2.930 |
Why?
|
| Apoptosis | 25 | 2023 | 774 | 2.550 |
Why?
|
| Uterine Cervical Neoplasms | 13 | 2025 | 298 | 2.540 |
Why?
|
| Retinoids | 16 | 2006 | 38 | 2.120 |
Why?
|
| Endometrial Neoplasms | 6 | 2023 | 189 | 1.790 |
Why?
|
| Cell Line, Tumor | 33 | 2025 | 1327 | 1.760 |
Why?
|
| Female | 68 | 2025 | 15191 | 1.460 |
Why?
|
| Tretinoin | 8 | 2014 | 17 | 1.340 |
Why?
|
| Receptors, Retinoic Acid | 15 | 2014 | 32 | 1.340 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2020 | 103 | 1.310 |
Why?
|
| Humans | 96 | 2025 | 28167 | 1.290 |
Why?
|
| Biomarkers, Tumor | 9 | 2021 | 406 | 1.210 |
Why?
|
| Angiogenesis Inhibitors | 6 | 2014 | 109 | 1.150 |
Why?
|
| Thalidomide | 4 | 2012 | 13 | 1.080 |
Why?
|
| Molecular Targeted Therapy | 4 | 2021 | 135 | 0.940 |
Why?
|
| Animals | 41 | 2025 | 10416 | 0.930 |
Why?
|
| Epithelial Cells | 2 | 2024 | 247 | 0.920 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2024 | 8 | 0.920 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2025 | 76 | 0.920 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2024 | 17 | 0.920 |
Why?
|
| Cyclin D1 | 7 | 2023 | 38 | 0.920 |
Why?
|
| 8,11,14-Eicosatrienoic Acid | 1 | 2024 | 5 | 0.910 |
Why?
|
| Thiourea | 6 | 2019 | 17 | 0.890 |
Why?
|
| Spheroids, Cellular | 1 | 2024 | 54 | 0.890 |
Why?
|
| Cell Proliferation | 15 | 2023 | 806 | 0.880 |
Why?
|
| Protein Kinases | 1 | 2025 | 158 | 0.870 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2014 | 120 | 0.830 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 2 | 2020 | 52 | 0.820 |
Why?
|
| Quinolines | 2 | 2019 | 25 | 0.800 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2022 | 113 | 0.780 |
Why?
|
| Mice | 24 | 2025 | 4655 | 0.780 |
Why?
|
| Blood Platelets | 1 | 2024 | 206 | 0.770 |
Why?
|
| Cell Culture Techniques | 2 | 2024 | 116 | 0.760 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2018 | 248 | 0.750 |
Why?
|
| HSC70 Heat-Shock Proteins | 1 | 2021 | 7 | 0.750 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2020 | 411 | 0.680 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2023 | 330 | 0.670 |
Why?
|
| Aza Compounds | 1 | 2020 | 11 | 0.660 |
Why?
|
| Radiation-Sensitizing Agents | 4 | 2017 | 32 | 0.660 |
Why?
|
| Uterine Neoplasms | 2 | 2012 | 71 | 0.640 |
Why?
|
| Retinoid X Receptors | 7 | 2014 | 24 | 0.630 |
Why?
|
| Endometrium | 2 | 2014 | 39 | 0.630 |
Why?
|
| Fallopian Tubes | 1 | 2018 | 15 | 0.580 |
Why?
|
| Autophagy | 3 | 2021 | 71 | 0.580 |
Why?
|
| Specimen Handling | 1 | 2018 | 33 | 0.570 |
Why?
|
| Tumor Cells, Cultured | 18 | 2016 | 315 | 0.570 |
Why?
|
| Structure-Activity Relationship | 10 | 2019 | 211 | 0.560 |
Why?
|
| Cell Survival | 7 | 2011 | 408 | 0.560 |
Why?
|
| Cancer Survivors | 1 | 2018 | 43 | 0.560 |
Why?
|
| Neovascularization, Pathologic | 5 | 2013 | 149 | 0.540 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2016 | 32 | 0.500 |
Why?
|
| Neoplasms | 4 | 2021 | 818 | 0.490 |
Why?
|
| Xenograft Model Antitumor Assays | 8 | 2020 | 270 | 0.480 |
Why?
|
| Administration, Oral | 8 | 2020 | 190 | 0.470 |
Why?
|
| Inflammation | 2 | 2016 | 633 | 0.450 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2017 | 465 | 0.450 |
Why?
|
| Mitochondria | 3 | 2025 | 366 | 0.450 |
Why?
|
| Cognitive Dysfunction | 1 | 2018 | 272 | 0.440 |
Why?
|
| Cell Cycle | 4 | 2024 | 161 | 0.440 |
Why?
|
| Uterine Cervical Dysplasia | 3 | 2020 | 35 | 0.440 |
Why?
|
| Benzoates | 3 | 2004 | 30 | 0.440 |
Why?
|
| Middle Aged | 15 | 2025 | 7164 | 0.440 |
Why?
|
| Aging | 2 | 2019 | 976 | 0.430 |
Why?
|
| Cell Division | 11 | 2007 | 154 | 0.430 |
Why?
|
| Vitamin A | 1 | 2014 | 26 | 0.430 |
Why?
|
| Shc Signaling Adaptor Proteins | 1 | 2013 | 8 | 0.430 |
Why?
|
| Aged | 12 | 2025 | 5416 | 0.430 |
Why?
|
| Urea | 3 | 2019 | 16 | 0.420 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2013 | 13 | 0.420 |
Why?
|
| Intestinal Neoplasms | 1 | 2013 | 15 | 0.420 |
Why?
|
| Drug Screening Assays, Antitumor | 9 | 2020 | 103 | 0.420 |
Why?
|
| Microspheres | 1 | 2013 | 49 | 0.420 |
Why?
|
| Obesity | 2 | 2016 | 668 | 0.410 |
Why?
|
| Breast Neoplasms | 2 | 2018 | 464 | 0.410 |
Why?
|
| Intestine, Small | 1 | 2013 | 67 | 0.410 |
Why?
|
| Peritoneal Neoplasms | 2 | 2011 | 79 | 0.410 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 2 | 2009 | 4 | 0.400 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2023 | 156 | 0.400 |
Why?
|
| Unfolded Protein Response | 1 | 2012 | 25 | 0.400 |
Why?
|
| Angiogenic Proteins | 1 | 2012 | 4 | 0.390 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2013 | 67 | 0.390 |
Why?
|
| Aged, 80 and over | 8 | 2018 | 2021 | 0.390 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2012 | 38 | 0.390 |
Why?
|
| Carcinosarcoma | 1 | 2012 | 22 | 0.390 |
Why?
|
| Insulin | 1 | 2014 | 315 | 0.390 |
Why?
|
| Transcription Factors | 7 | 2013 | 522 | 0.380 |
Why?
|
| NF-kappa B | 2 | 2010 | 191 | 0.380 |
Why?
|
| Lymph Nodes | 2 | 2023 | 103 | 0.380 |
Why?
|
| Tamoxifen | 2 | 2015 | 33 | 0.370 |
Why?
|
| Colonic Neoplasms | 1 | 2013 | 122 | 0.370 |
Why?
|
| Neoplasms, Glandular and Epithelial | 4 | 2018 | 72 | 0.360 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2011 | 33 | 0.360 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2013 | 167 | 0.360 |
Why?
|
| Signal Transduction | 9 | 2017 | 1433 | 0.360 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2025 | 164 | 0.360 |
Why?
|
| Vascular Endothelial Growth Factor A | 7 | 2017 | 179 | 0.350 |
Why?
|
| Src Homology 2 Domain-Containing, Transforming Protein 1 | 2 | 2025 | 10 | 0.350 |
Why?
|
| Dose-Response Relationship, Drug | 11 | 2020 | 608 | 0.340 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2010 | 52 | 0.330 |
Why?
|
| Mice, Nude | 5 | 2020 | 330 | 0.320 |
Why?
|
| Antibodies | 2 | 2018 | 124 | 0.320 |
Why?
|
| Cyclins | 1 | 2009 | 8 | 0.320 |
Why?
|
| G1 Phase | 1 | 2009 | 17 | 0.320 |
Why?
|
| DNA Damage | 4 | 2019 | 149 | 0.310 |
Why?
|
| Cell Communication | 2 | 2024 | 68 | 0.310 |
Why?
|
| Biomarkers | 4 | 2022 | 763 | 0.310 |
Why?
|
| Adult | 11 | 2025 | 7765 | 0.300 |
Why?
|
| Repressor Proteins | 2 | 2024 | 118 | 0.300 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2012 | 258 | 0.290 |
Why?
|
| Reactive Oxygen Species | 4 | 2011 | 284 | 0.290 |
Why?
|
| Kidney Neoplasms | 1 | 2009 | 103 | 0.290 |
Why?
|
| Leiomyosarcoma | 1 | 2007 | 10 | 0.280 |
Why?
|
| Protein Binding | 5 | 2024 | 657 | 0.270 |
Why?
|
| Models, Biological | 4 | 2020 | 465 | 0.270 |
Why?
|
| Clioquinol | 3 | 2011 | 11 | 0.260 |
Why?
|
| Hysterectomy | 2 | 2025 | 85 | 0.260 |
Why?
|
| Transcription, Genetic | 7 | 2011 | 402 | 0.260 |
Why?
|
| Neoplasm Proteins | 3 | 2016 | 123 | 0.250 |
Why?
|
| Immunotoxins | 2 | 2002 | 3 | 0.250 |
Why?
|
| Phenylurea Compounds | 1 | 2005 | 16 | 0.240 |
Why?
|
| Transcriptional Activation | 5 | 2003 | 86 | 0.240 |
Why?
|
| Fenretinide | 2 | 2002 | 4 | 0.240 |
Why?
|
| Renal Circulation | 1 | 2025 | 7 | 0.240 |
Why?
|
| Toluene | 1 | 2005 | 11 | 0.240 |
Why?
|
| Nephritis | 1 | 2025 | 10 | 0.240 |
Why?
|
| Perimenopause | 1 | 2025 | 6 | 0.230 |
Why?
|
| Platelet Aggregation | 1 | 2024 | 44 | 0.220 |
Why?
|
| Suppositories | 3 | 2020 | 7 | 0.220 |
Why?
|
| Mycobacterium bovis | 1 | 2004 | 3 | 0.220 |
Why?
|
| Lymphatic Metastasis | 2 | 2022 | 125 | 0.220 |
Why?
|
| Genes | 3 | 1988 | 36 | 0.220 |
Why?
|
| Cell Differentiation | 6 | 2006 | 407 | 0.220 |
Why?
|
| Benzopyrans | 1 | 2004 | 22 | 0.220 |
Why?
|
| Iron | 1 | 2025 | 116 | 0.210 |
Why?
|
| Transfection | 6 | 2009 | 318 | 0.210 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2018 | 233 | 0.210 |
Why?
|
| Kidney | 1 | 2025 | 286 | 0.210 |
Why?
|
| Rats | 8 | 2025 | 1568 | 0.210 |
Why?
|
| Niclosamide | 1 | 2023 | 3 | 0.200 |
Why?
|
| Lung Neoplasms | 3 | 2016 | 356 | 0.200 |
Why?
|
| Pelvis | 1 | 2023 | 38 | 0.200 |
Why?
|
| Prealbumin | 1 | 2022 | 4 | 0.200 |
Why?
|
| Molecular Docking Simulation | 2 | 2019 | 51 | 0.200 |
Why?
|
| Lymph Node Excision | 1 | 2023 | 100 | 0.200 |
Why?
|
| Transcription Factor AP-1 | 2 | 1999 | 26 | 0.200 |
Why?
|
| Pilot Projects | 3 | 2022 | 436 | 0.200 |
Why?
|
| Menstrual Cycle | 1 | 2002 | 24 | 0.200 |
Why?
|
| Mice, Inbred C57BL | 3 | 2017 | 1573 | 0.200 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2002 | 24 | 0.200 |
Why?
|
| Anticarcinogenic Agents | 2 | 2012 | 16 | 0.190 |
Why?
|
| Head and Neck Neoplasms | 2 | 2003 | 87 | 0.190 |
Why?
|
| Hypertension | 1 | 2025 | 309 | 0.190 |
Why?
|
| Oncogenes | 1 | 2022 | 34 | 0.190 |
Why?
|
| Lysosomes | 3 | 2023 | 56 | 0.190 |
Why?
|
| Cancer Vaccines | 1 | 2021 | 33 | 0.190 |
Why?
|
| Cognition | 1 | 2025 | 324 | 0.190 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2001 | 5 | 0.180 |
Why?
|
| Isoxazoles | 1 | 2001 | 8 | 0.180 |
Why?
|
| Disease-Free Survival | 5 | 2014 | 238 | 0.180 |
Why?
|
| Cloning, Molecular | 3 | 2014 | 207 | 0.180 |
Why?
|
| Interleukin-6 | 2 | 2022 | 194 | 0.180 |
Why?
|
| Mebendazole | 1 | 2020 | 10 | 0.170 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2012 | 80 | 0.170 |
Why?
|
| Proteomics | 1 | 2022 | 181 | 0.170 |
Why?
|
| Receptors, Thyroid Hormone | 3 | 1994 | 8 | 0.170 |
Why?
|
| Cell Movement | 4 | 2017 | 373 | 0.170 |
Why?
|
| Carcinoma | 1 | 2001 | 75 | 0.170 |
Why?
|
| Drug Delivery Systems | 3 | 2017 | 225 | 0.170 |
Why?
|
| Biological Availability | 5 | 2020 | 44 | 0.170 |
Why?
|
| ErbB Receptors | 2 | 1997 | 101 | 0.170 |
Why?
|
| African Americans | 1 | 2022 | 350 | 0.160 |
Why?
|
| Maintenance Chemotherapy | 1 | 2020 | 17 | 0.160 |
Why?
|
| Hydrogen Peroxide | 2 | 2010 | 144 | 0.160 |
Why?
|
| Benzamides | 1 | 1999 | 34 | 0.160 |
Why?
|
| RNA, Small Interfering | 3 | 2017 | 198 | 0.160 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1999 | 31 | 0.160 |
Why?
|
| Brain | 1 | 2025 | 739 | 0.160 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 1 | 2019 | 15 | 0.160 |
Why?
|
| Proto-Oncogenes | 2 | 1990 | 15 | 0.150 |
Why?
|
| PPAR alpha | 2 | 2009 | 33 | 0.150 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2019 | 48 | 0.150 |
Why?
|
| Binding Sites | 1 | 2019 | 354 | 0.150 |
Why?
|
| Adenocarcinoma | 2 | 2025 | 297 | 0.150 |
Why?
|
| Diestrus | 1 | 2018 | 2 | 0.150 |
Why?
|
| Estrus | 1 | 2018 | 23 | 0.150 |
Why?
|
| DNA-Binding Proteins | 3 | 2013 | 491 | 0.150 |
Why?
|
| Oxyhemoglobins | 1 | 2018 | 10 | 0.150 |
Why?
|
| Salpingectomy | 1 | 2018 | 8 | 0.150 |
Why?
|
| Drug Synergism | 4 | 2020 | 104 | 0.140 |
Why?
|
| Food, Formulated | 1 | 2017 | 11 | 0.140 |
Why?
|
| Emulsifying Agents | 1 | 2017 | 7 | 0.140 |
Why?
|
| Chemoprevention | 1 | 2017 | 32 | 0.140 |
Why?
|
| C-Reactive Protein | 1 | 2018 | 92 | 0.140 |
Why?
|
| Docosahexaenoic Acids | 2 | 2009 | 105 | 0.140 |
Why?
|
| Prodrugs | 1 | 2018 | 30 | 0.140 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 2 | 1994 | 27 | 0.140 |
Why?
|
| Mutation | 2 | 2020 | 849 | 0.140 |
Why?
|
| Oxygen Consumption | 1 | 2018 | 181 | 0.140 |
Why?
|
| Vulvar Neoplasms | 1 | 1997 | 25 | 0.140 |
Why?
|
| Body Mass Index | 2 | 2016 | 398 | 0.140 |
Why?
|
| Celecoxib | 1 | 2017 | 10 | 0.140 |
Why?
|
| Carcinoma in Situ | 1 | 2017 | 46 | 0.130 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2008 | 105 | 0.130 |
Why?
|
| Cell Line | 4 | 2010 | 694 | 0.130 |
Why?
|
| Polycomb Repressive Complex 1 | 1 | 2017 | 34 | 0.130 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 2 | 1994 | 25 | 0.130 |
Why?
|
| Cervical Intraepithelial Neoplasia | 1 | 2017 | 83 | 0.130 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2017 | 36 | 0.130 |
Why?
|
| Retrospective Studies | 3 | 2022 | 2558 | 0.130 |
Why?
|
| Natural Killer T-Cells | 1 | 2017 | 55 | 0.130 |
Why?
|
| Neuropilin-1 | 1 | 2016 | 5 | 0.130 |
Why?
|
| Male | 8 | 2025 | 13510 | 0.130 |
Why?
|
| Tissue Array Analysis | 1 | 2016 | 24 | 0.130 |
Why?
|
| Mice, Knockout | 3 | 2017 | 847 | 0.130 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2018 | 301 | 0.120 |
Why?
|
| Endometrial Hyperplasia | 1 | 2015 | 6 | 0.120 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 1995 | 19 | 0.120 |
Why?
|
| Protein Precursors | 1 | 1995 | 11 | 0.120 |
Why?
|
| Cisplatin | 2 | 2009 | 179 | 0.120 |
Why?
|
| DNA | 4 | 1994 | 374 | 0.120 |
Why?
|
| Mutagenicity Tests | 3 | 2012 | 4 | 0.120 |
Why?
|
| Area Under Curve | 4 | 2020 | 95 | 0.120 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2015 | 29 | 0.120 |
Why?
|
| Triazines | 1 | 2014 | 11 | 0.110 |
Why?
|
| Caspase 3 | 3 | 2010 | 58 | 0.110 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2016 | 162 | 0.110 |
Why?
|
| Alanine | 1 | 2014 | 40 | 0.110 |
Why?
|
| Macrophages | 1 | 2017 | 296 | 0.110 |
Why?
|
| Administration, Intravaginal | 3 | 2018 | 12 | 0.110 |
Why?
|
| Subcutaneous Fat | 1 | 2014 | 17 | 0.110 |
Why?
|
| Tissue Culture Techniques | 1 | 2014 | 31 | 0.110 |
Why?
|
| Intra-Abdominal Fat | 1 | 2014 | 21 | 0.110 |
Why?
|
| Primary Cell Culture | 1 | 2014 | 30 | 0.110 |
Why?
|
| Response Elements | 1 | 2014 | 22 | 0.110 |
Why?
|
| Magnetic Phenomena | 1 | 2013 | 7 | 0.110 |
Why?
|
| History, 21st Century | 1 | 2014 | 49 | 0.110 |
Why?
|
| Molecular Sequence Data | 7 | 2011 | 1052 | 0.110 |
Why?
|
| History, 20th Century | 1 | 2014 | 84 | 0.110 |
Why?
|
| Intestinal Polyps | 1 | 2013 | 6 | 0.110 |
Why?
|
| Protein Isoforms | 1 | 2014 | 119 | 0.110 |
Why?
|
| Endonucleases | 1 | 2013 | 16 | 0.100 |
Why?
|
| Protein Structure, Tertiary | 1 | 2014 | 284 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 144 | 0.100 |
Why?
|
| Heart Diseases | 1 | 2013 | 70 | 0.100 |
Why?
|
| Gene Expression | 2 | 2011 | 416 | 0.100 |
Why?
|
| Combined Modality Therapy | 2 | 2005 | 302 | 0.100 |
Why?
|
| Paclitaxel | 2 | 2014 | 190 | 0.100 |
Why?
|
| Protein Folding | 1 | 2012 | 47 | 0.100 |
Why?
|
| Poly(ADP-ribose) Polymerases | 2 | 2010 | 22 | 0.100 |
Why?
|
| Proteolysis | 1 | 2012 | 58 | 0.100 |
Why?
|
| Mutagens | 1 | 2012 | 7 | 0.100 |
Why?
|
| Organophosphates | 1 | 2012 | 4 | 0.100 |
Why?
|
| Gene Expression Regulation | 3 | 2014 | 633 | 0.100 |
Why?
|
| Ibuprofen | 1 | 2012 | 17 | 0.100 |
Why?
|
| Base Sequence | 6 | 2011 | 585 | 0.100 |
Why?
|
| Glutathione | 2 | 2009 | 76 | 0.090 |
Why?
|
| Down-Regulation | 2 | 2011 | 198 | 0.090 |
Why?
|
| Half-Life | 3 | 2020 | 34 | 0.090 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 224 | 0.090 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2005 | 36 | 0.090 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2011 | 20 | 0.090 |
Why?
|
| Survival Analysis | 1 | 2012 | 289 | 0.090 |
Why?
|
| Nitroquinolines | 1 | 2011 | 2 | 0.090 |
Why?
|
| Proportional Hazards Models | 2 | 2014 | 226 | 0.090 |
Why?
|
| Time Factors | 3 | 2018 | 1593 | 0.090 |
Why?
|
| Pyrimidines | 1 | 2012 | 126 | 0.090 |
Why?
|
| Pancreatic Neoplasms | 1 | 2017 | 534 | 0.090 |
Why?
|
| Protein Kinase C | 1 | 2011 | 73 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 192 | 0.090 |
Why?
|
| Endothelial Protein C Receptor | 2 | 2007 | 7 | 0.090 |
Why?
|
| Organoplatinum Compounds | 1 | 2010 | 24 | 0.090 |
Why?
|
| Bridged-Ring Compounds | 1 | 2010 | 18 | 0.090 |
Why?
|
| Survival Rate | 2 | 2025 | 430 | 0.090 |
Why?
|
| CA-125 Antigen | 1 | 2010 | 19 | 0.090 |
Why?
|
| Endpoint Determination | 1 | 2010 | 18 | 0.090 |
Why?
|
| Fibroblast Growth Factor 2 | 2 | 2007 | 29 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2013 | 555 | 0.090 |
Why?
|
| Retinoic Acid Receptor alpha | 3 | 1999 | 5 | 0.090 |
Why?
|
| Taxoids | 1 | 2010 | 37 | 0.090 |
Why?
|
| Acetylcysteine | 1 | 2010 | 24 | 0.080 |
Why?
|
| Recombinant Proteins | 2 | 2009 | 414 | 0.080 |
Why?
|
| Blotting, Western | 4 | 2016 | 513 | 0.080 |
Why?
|
| I-kappa B Kinase | 1 | 2010 | 8 | 0.080 |
Why?
|
| Indoles | 1 | 2011 | 99 | 0.080 |
Why?
|
| Copper | 1 | 2010 | 47 | 0.080 |
Why?
|
| Enzyme Inhibitors | 1 | 2011 | 250 | 0.080 |
Why?
|
| Receptors, Cell Surface | 2 | 2007 | 114 | 0.080 |
Why?
|
| Genetic Variation | 1 | 2011 | 243 | 0.080 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2009 | 11 | 0.080 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2011 | 157 | 0.080 |
Why?
|
| Antigens, CD | 2 | 2007 | 140 | 0.080 |
Why?
|
| Carbon-Sulfur Lyases | 1 | 2009 | 16 | 0.080 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2009 | 42 | 0.080 |
Why?
|
| Ubiquitination | 1 | 2009 | 32 | 0.080 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2009 | 31 | 0.080 |
Why?
|
| Treatment Outcome | 2 | 2014 | 2383 | 0.080 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2009 | 8 | 0.080 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2009 | 58 | 0.080 |
Why?
|
| Administration, Intravenous | 2 | 2020 | 30 | 0.080 |
Why?
|
| Superoxide Dismutase | 1 | 2009 | 70 | 0.080 |
Why?
|
| Gene Expression Profiling | 1 | 2011 | 451 | 0.080 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2008 | 1 | 0.080 |
Why?
|
| Mice, Inbred Strains | 2 | 2006 | 61 | 0.080 |
Why?
|
| Thymidine Phosphorylase | 1 | 2008 | 2 | 0.080 |
Why?
|
| Molecular Structure | 3 | 2015 | 243 | 0.080 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2009 | 102 | 0.080 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2009 | 55 | 0.080 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2008 | 49 | 0.070 |
Why?
|
| Transcription Factor CHOP | 1 | 2008 | 7 | 0.070 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2008 | 5 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2019 | 544 | 0.070 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2008 | 49 | 0.070 |
Why?
|
| Chromatography, Liquid | 1 | 2008 | 76 | 0.070 |
Why?
|
| In Situ Nick-End Labeling | 3 | 2006 | 43 | 0.070 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 2008 | 12 | 0.070 |
Why?
|
| Dogs | 3 | 2018 | 509 | 0.070 |
Why?
|
| Phosphorylation | 1 | 2009 | 578 | 0.070 |
Why?
|
| Molecular Chaperones | 1 | 2008 | 48 | 0.070 |
Why?
|
| Testis | 1 | 1987 | 35 | 0.070 |
Why?
|
| Ligands | 3 | 2009 | 176 | 0.070 |
Why?
|
| Phenotype | 2 | 2017 | 679 | 0.070 |
Why?
|
| Disease Models, Animal | 2 | 2025 | 1462 | 0.070 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 1988 | 131 | 0.070 |
Why?
|
| Papillomaviridae | 2 | 2017 | 88 | 0.070 |
Why?
|
| Amino Acid Sequence | 4 | 2016 | 690 | 0.070 |
Why?
|
| Rhodamines | 1 | 2006 | 10 | 0.070 |
Why?
|
| Carrier Proteins | 1 | 1988 | 252 | 0.060 |
Why?
|
| Liver Neoplasms | 1 | 1988 | 166 | 0.060 |
Why?
|
| Choriocarcinoma | 1 | 2006 | 6 | 0.060 |
Why?
|
| Norfloxacin | 1 | 1986 | 4 | 0.060 |
Why?
|
| Skin Irritancy Tests | 1 | 2005 | 4 | 0.060 |
Why?
|
| Alanine Transaminase | 1 | 2005 | 27 | 0.060 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2006 | 131 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 3 | 1997 | 269 | 0.060 |
Why?
|
| Papillomavirus Infections | 2 | 2017 | 144 | 0.060 |
Why?
|
| Hypertension, Renal | 1 | 2025 | 6 | 0.060 |
Why?
|
| Endothelial Cells | 1 | 2008 | 362 | 0.060 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2025 | 12 | 0.060 |
Why?
|
| Benzothiazoles | 1 | 2005 | 5 | 0.060 |
Why?
|
| Genes, fos | 1 | 2005 | 13 | 0.060 |
Why?
|
| Species Specificity | 2 | 2018 | 192 | 0.060 |
Why?
|
| Rats, Inbred Dahl | 1 | 2025 | 16 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 215 | 0.060 |
Why?
|
| Cervix Uteri | 2 | 2018 | 65 | 0.060 |
Why?
|
| Arterioles | 1 | 2025 | 61 | 0.060 |
Why?
|
| Pseudomonas aeruginosa | 1 | 1986 | 71 | 0.060 |
Why?
|
| Vasoconstriction | 1 | 2025 | 45 | 0.060 |
Why?
|
| Thiazoles | 1 | 2005 | 51 | 0.060 |
Why?
|
| RNA | 1 | 2005 | 111 | 0.060 |
Why?
|
| Promoter Regions, Genetic | 3 | 2011 | 345 | 0.060 |
Why?
|
| Cells, Cultured | 3 | 2002 | 985 | 0.060 |
Why?
|
| Immunohistochemistry | 2 | 2002 | 463 | 0.060 |
Why?
|
| Disease Progression | 2 | 2017 | 474 | 0.060 |
Why?
|
| Sulfur | 2 | 2018 | 35 | 0.060 |
Why?
|
| DNA, Bacterial | 1 | 1986 | 306 | 0.060 |
Why?
|
| Heterografts | 1 | 2023 | 66 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 2 | 2002 | 329 | 0.050 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 2003 | 10 | 0.050 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2004 | 148 | 0.050 |
Why?
|
| Cathepsin B | 1 | 2023 | 4 | 0.050 |
Why?
|
| Interleukin-8 | 1 | 2022 | 45 | 0.050 |
Why?
|
| Computer Simulation | 1 | 2004 | 230 | 0.050 |
Why?
|
| Cohort Studies | 1 | 2025 | 889 | 0.050 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2022 | 33 | 0.050 |
Why?
|
| Vitamin D | 1 | 2022 | 50 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2022 | 114 | 0.050 |
Why?
|
| Prognosis | 2 | 2016 | 803 | 0.050 |
Why?
|
| Premenopause | 1 | 2002 | 20 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-jun | 2 | 1994 | 12 | 0.050 |
Why?
|
| Goats | 1 | 2002 | 11 | 0.050 |
Why?
|
| Neutralization Tests | 1 | 2002 | 34 | 0.050 |
Why?
|
| Stromal Cells | 1 | 2002 | 61 | 0.050 |
Why?
|
| Molecular Mimicry | 1 | 2002 | 30 | 0.050 |
Why?
|
| Genital Neoplasms, Female | 1 | 2002 | 67 | 0.050 |
Why?
|
| Tissue Distribution | 2 | 2020 | 137 | 0.050 |
Why?
|
| RNA, Messenger | 3 | 2011 | 658 | 0.050 |
Why?
|
| Drug Design | 1 | 2002 | 63 | 0.050 |
Why?
|
| Mass Spectrometry | 2 | 2006 | 190 | 0.050 |
Why?
|
| Progesterone | 1 | 2002 | 129 | 0.050 |
Why?
|
| Estradiol | 1 | 2002 | 175 | 0.050 |
Why?
|
| Membrane Glycoproteins | 1 | 2002 | 145 | 0.050 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2001 | 35 | 0.050 |
Why?
|
| Drug Resistance, Multiple | 1 | 2001 | 20 | 0.050 |
Why?
|
| Ki-67 Antigen | 1 | 2001 | 23 | 0.050 |
Why?
|
| Autophagosomes | 1 | 2021 | 5 | 0.040 |
Why?
|
| Autophagy-Related Proteins | 1 | 2021 | 9 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2001 | 82 | 0.040 |
Why?
|
| Biological Assay | 1 | 2021 | 35 | 0.040 |
Why?
|
| Fenbendazole | 1 | 2020 | 8 | 0.040 |
Why?
|
| Quinuclidines | 1 | 2020 | 10 | 0.040 |
Why?
|
| Mucin-1 | 1 | 2001 | 35 | 0.040 |
Why?
|
| Drug Repositioning | 1 | 2020 | 12 | 0.040 |
Why?
|
| Kinetics | 3 | 2006 | 545 | 0.040 |
Why?
|
| Random Allocation | 1 | 2020 | 151 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2002 | 270 | 0.040 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 1999 | 164 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2025 | 826 | 0.040 |
Why?
|
| Gene Silencing | 2 | 2011 | 65 | 0.040 |
Why?
|
| Transglutaminases | 1 | 1999 | 8 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 1999 | 90 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2002 | 775 | 0.040 |
Why?
|
| Rodentia | 1 | 2019 | 14 | 0.040 |
Why?
|
| United States | 1 | 2025 | 2151 | 0.040 |
Why?
|
| Urothelium | 1 | 1999 | 35 | 0.040 |
Why?
|
| Geriatrics | 1 | 2019 | 47 | 0.040 |
Why?
|
| Carcinogenesis | 1 | 2019 | 84 | 0.040 |
Why?
|
| Research | 1 | 2019 | 92 | 0.040 |
Why?
|
| Solubility | 1 | 2018 | 73 | 0.040 |
Why?
|
| Cystathionine gamma-Lyase | 1 | 2018 | 7 | 0.040 |
Why?
|
| Microscopy, Confocal | 2 | 2010 | 113 | 0.040 |
Why?
|
| 5'-Nucleotidase | 1 | 2018 | 13 | 0.040 |
Why?
|
| OX40 Ligand | 1 | 2018 | 16 | 0.040 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2018 | 30 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2022 | 613 | 0.040 |
Why?
|
| Annexin A5 | 1 | 2018 | 24 | 0.040 |
Why?
|
| Models, Molecular | 1 | 1999 | 453 | 0.040 |
Why?
|
| Longevity | 1 | 2019 | 134 | 0.040 |
Why?
|
| Protein Biosynthesis | 2 | 1988 | 111 | 0.040 |
Why?
|
| Granuloma, Pyogenic | 1 | 1997 | 3 | 0.040 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2017 | 27 | 0.040 |
Why?
|
| Tumor Virus Infections | 1 | 1997 | 14 | 0.040 |
Why?
|
| Mouth Diseases | 1 | 1997 | 6 | 0.040 |
Why?
|
| Retinol-Binding Proteins, Cellular | 1 | 1997 | 1 | 0.030 |
Why?
|
| Adolescent | 2 | 2017 | 3128 | 0.030 |
Why?
|
| Cobalt Radioisotopes | 1 | 1997 | 1 | 0.030 |
Why?
|
| Retinol-Binding Proteins | 1 | 1997 | 7 | 0.030 |
Why?
|
| Prostaglandin-E Synthases | 1 | 2017 | 6 | 0.030 |
Why?
|
| CD8 Antigens | 1 | 2017 | 10 | 0.030 |
Why?
|
| Arachidonate 5-Lipoxygenase | 1 | 2017 | 12 | 0.030 |
Why?
|
| Genes, ras | 1 | 2017 | 12 | 0.030 |
Why?
|
| Lipoxygenase Inhibitors | 1 | 2017 | 16 | 0.030 |
Why?
|
| DNA, Viral | 1 | 1997 | 56 | 0.030 |
Why?
|
| Skin Diseases | 1 | 1997 | 29 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 163 | 0.030 |
Why?
|
| Radiation Tolerance | 1 | 1997 | 32 | 0.030 |
Why?
|
| Oxygen | 1 | 2018 | 234 | 0.030 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2017 | 19 | 0.030 |
Why?
|
| Antigens, CD1d | 1 | 2017 | 45 | 0.030 |
Why?
|
| Cyclooxygenase 2 | 1 | 2017 | 68 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 1997 | 180 | 0.030 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2017 | 45 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2018 | 158 | 0.030 |
Why?
|
| Quantum Theory | 1 | 2016 | 22 | 0.030 |
Why?
|
| Progesterone Congeners | 1 | 2015 | 4 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2017 | 417 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 327 | 0.030 |
Why?
|
| Neoplastic Stem Cells | 1 | 2017 | 142 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2016 | 104 | 0.030 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2015 | 37 | 0.030 |
Why?
|
| Phosphoproteins | 1 | 2016 | 119 | 0.030 |
Why?
|
| Organ Culture Techniques | 1 | 1995 | 56 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 1997 | 247 | 0.030 |
Why?
|
| Mucins | 1 | 1995 | 24 | 0.030 |
Why?
|
| Disease Management | 1 | 2015 | 88 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2016 | 288 | 0.030 |
Why?
|
| HeLa Cells | 1 | 1995 | 208 | 0.030 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 1994 | 24 | 0.030 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2014 | 13 | 0.030 |
Why?
|
| Thyroid Hormones | 1 | 1994 | 36 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 677 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2016 | 724 | 0.030 |
Why?
|
| Carboplatin | 1 | 2014 | 111 | 0.030 |
Why?
|
| Bevacizumab | 1 | 2014 | 103 | 0.030 |
Why?
|
| Quality of Life | 1 | 2017 | 492 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 300 | 0.030 |
Why?
|
| Adiposity | 1 | 2014 | 94 | 0.030 |
Why?
|
| Platinum | 1 | 2013 | 18 | 0.030 |
Why?
|
| Overweight | 1 | 2014 | 111 | 0.030 |
Why?
|
| No-Observed-Adverse-Effect Level | 1 | 2012 | 1 | 0.030 |
Why?
|
| Toxicity Tests | 1 | 2012 | 10 | 0.020 |
Why?
|
| Adrenal Glands | 1 | 2012 | 21 | 0.020 |
Why?
|
| Organ Size | 1 | 2012 | 86 | 0.020 |
Why?
|
| Micronucleus Tests | 1 | 2012 | 2 | 0.020 |
Why?
|
| Prostate | 1 | 2012 | 52 | 0.020 |
Why?
|
| Eating | 1 | 2012 | 70 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2012 | 37 | 0.020 |
Why?
|
| Cricetulus | 1 | 2012 | 56 | 0.020 |
Why?
|
| CHO Cells | 1 | 2012 | 97 | 0.020 |
Why?
|
| Cricetinae | 1 | 2012 | 130 | 0.020 |
Why?
|
| Weight Gain | 1 | 2012 | 75 | 0.020 |
Why?
|
| Genotype | 1 | 2013 | 457 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2013 | 247 | 0.020 |
Why?
|
| Azacitidine | 1 | 2011 | 8 | 0.020 |
Why?
|
| Rats, Inbred F344 | 1 | 2012 | 174 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2011 | 67 | 0.020 |
Why?
|
| 3' Untranslated Regions | 1 | 2011 | 34 | 0.020 |
Why?
|
| Salmonella typhimurium | 1 | 2012 | 68 | 0.020 |
Why?
|
| HL-60 Cells | 1 | 2011 | 22 | 0.020 |
Why?
|
| Motor Activity | 1 | 2012 | 147 | 0.020 |
Why?
|
| Wnt Proteins | 1 | 2011 | 34 | 0.020 |
Why?
|
| Reference Standards | 1 | 2011 | 57 | 0.020 |
Why?
|
| beta Catenin | 1 | 2011 | 66 | 0.020 |
Why?
|
| Protein Kinase C beta | 1 | 2011 | 4 | 0.020 |
Why?
|
| Disease | 1 | 2011 | 15 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 133 | 0.020 |
Why?
|
| Genes, p53 | 1 | 2011 | 14 | 0.020 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2011 | 15 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 477 | 0.020 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2011 | 31 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2011 | 58 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2011 | 190 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2006 | 521 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2011 | 124 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2011 | 76 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2011 | 136 | 0.020 |
Why?
|
| Risk Factors | 1 | 2015 | 2087 | 0.020 |
Why?
|
| Oligonucleotide Probes | 1 | 1990 | 18 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2011 | 153 | 0.020 |
Why?
|
| Gene Library | 1 | 1990 | 45 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2011 | 147 | 0.020 |
Why?
|
| Macromolecular Substances | 1 | 1990 | 53 | 0.020 |
Why?
|
| Plasmids | 1 | 1990 | 125 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 1990 | 97 | 0.020 |
Why?
|
| Clofibrate | 1 | 2009 | 4 | 0.020 |
Why?
|
| Young Adult | 1 | 2017 | 2738 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 1990 | 116 | 0.020 |
Why?
|
| Superoxide Dismutase-1 | 1 | 2009 | 48 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2008 | 13 | 0.020 |
Why?
|
| Microsomes, Liver | 1 | 2008 | 11 | 0.020 |
Why?
|
| Jurkat Cells | 1 | 2008 | 30 | 0.020 |
Why?
|
| Galactosyltransferases | 1 | 2008 | 17 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2008 | 245 | 0.020 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2006 | 24 | 0.020 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2006 | 64 | 0.020 |
Why?
|
| Lasers | 1 | 2006 | 67 | 0.020 |
Why?
|
| Melanoma | 1 | 2008 | 153 | 0.020 |
Why?
|
| Drug Stability | 1 | 2006 | 23 | 0.020 |
Why?
|
| Colorectal Neoplasms | 1 | 2008 | 139 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2006 | 65 | 0.020 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 1986 | 14 | 0.020 |
Why?
|
| Recombination, Genetic | 1 | 1986 | 61 | 0.020 |
Why?
|
| DNA Replication | 1 | 1986 | 51 | 0.020 |
Why?
|
| DNA Repair | 1 | 1986 | 83 | 0.010 |
Why?
|
| Temperature | 1 | 2006 | 213 | 0.010 |
Why?
|
| Intracellular Membranes | 1 | 2003 | 15 | 0.010 |
Why?
|
| Membrane Potentials | 1 | 2003 | 62 | 0.010 |
Why?
|
| Caspases | 1 | 2003 | 42 | 0.010 |
Why?
|
| Permeability | 1 | 2003 | 61 | 0.010 |
Why?
|
| Embryo, Mammalian | 1 | 2003 | 29 | 0.010 |
Why?
|
| Immunoglobulin Fragments | 1 | 2002 | 6 | 0.010 |
Why?
|
| GPI-Linked Proteins | 1 | 2002 | 13 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2003 | 267 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2002 | 46 | 0.010 |
Why?
|
| Enterotoxins | 1 | 2002 | 22 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2002 | 55 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2002 | 155 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 1986 | 485 | 0.010 |
Why?
|
| Collagen | 1 | 2002 | 156 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 1986 | 523 | 0.010 |
Why?
|
| Proteins | 1 | 2002 | 252 | 0.010 |
Why?
|
| Liver | 1 | 2003 | 441 | 0.010 |
Why?
|
| Papilloma | 1 | 1999 | 2 | 0.010 |
Why?
|
| Simian virus 40 | 1 | 1999 | 8 | 0.010 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 1999 | 8 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 1999 | 42 | 0.010 |
Why?
|
| Pregnancy | 1 | 2003 | 1191 | 0.010 |
Why?
|
| Culture Techniques | 1 | 1997 | 12 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 1997 | 48 | 0.010 |
Why?
|
| Reference Values | 1 | 1997 | 200 | 0.010 |
Why?
|
| Incidence | 1 | 1999 | 562 | 0.010 |
Why?
|
| Orphan Nuclear Receptors | 1 | 1994 | 7 | 0.010 |
Why?
|
| Liver X Receptors | 1 | 1994 | 22 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1994 | 132 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 1994 | 369 | 0.010 |
Why?
|